Development and validation of bexarote by bioanalytical methods using liquid chromatography-tandem mass spectroscopy (LC-MS/MS)

• Published in: Future journal of pharmaceutical sciences 2021-01, Vol.7 (1), p.28-10, Article 28
• Main Authors: Nagaraju, K., Chowdary, Y. A., Rao, M. V. Basaveswara
• Format: Article
• Language: English
• Subjects: Accuracy; Bexarotene; Chromatography; Liquid chromatography; Mass spectrometer; Medicine; Medicine & Public Health; Pharmaceutical sciences; Plasma; Retention; Validation
• ISSN: 2314-7253; 2314-7245; 2314-7253
• DOI: 10.1186/s43094-020-00155-6

Background The aim of this study was to develop and validate accurate and precise UPLC method with tandem mass spectrometry (Waters) for the determination of bexarotene in human plasma using bexarotene D4 as internal standard (IS). Results The retention time of bexarotene was 2.75 ± 0.30 min. The method was validated with respect to system suitability, linearity, accuracy, precision, matrix effect, auto sampler carryover test, and recovery. Linearity was found to be 1.04 to 351.93 μg/mL. LOQQC, LQC, INTQC, MQC, and HQC were found to be 1.0550, 2.7800, 25.2700, 131.61, and 263.23 respectively. The mean percentage recovery was found to be 95.72% Conclusion The bioanalytical method, a selective and sensitive liquid chromatography-mass spectrometry method to quantitate bexarotene in K 2 EDTA human plasma over the concentration range 1.0440 to 351.9320 ng/mL, was successfully validated. This method is suitable for sample analysis to support bioequivalence/bioavailability and/or pharmacokinetic studies involving formulations of bexarotene.